BioVie (BIVI) Stock Price, News & Analysis

Company Overview

BioVie Inc. is a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapies for neurological and gastrointestinal disorders. The company’s lead investigational product, NE3107, is an oral anti-inflammatory and insulin-sensitizing agent being evaluated for the treatment of mild-to-moderate Alzheimer’s disease. In addition to its Alzheimer’s program, BioVie is advancing NE3107 in Phase II studies for diabetic and idiopathic gastroparesis, nonalcoholic steatohepatitis (NASH)-related cirrhosis with portal hypertension, and primary biliary cholangitis (PBC). These programs seek to address significant unmet medical needs by targeting common pathways of inflammation and metabolic dysfunction.

Founded in 2015 and headquartered in Alameda, California, the company has built a pipeline aimed at leveraging NE3107’s mechanism of action across multiple indications. BioVie has entered into strategic collaborations and licensing agreements to support its global clinical development. Notably, the company secured rights to conduct Phase II/III trials of NE3107 in the People’s Republic of China, expanding its geographic footprint and fostering research partnerships in Asia.

Research and development efforts are supported by a network of academic and clinical research institutions in North America and abroad. BioVie’s scientific advisory board includes experts in neurodegenerative and gastrointestinal diseases, guiding trial design and regulatory strategy. The company’s manufacturing and formulation capabilities enable scalable production of its oral drug candidates under current Good Manufacturing Practice (cGMP) standards.

BioVie is led by an executive team with decades of combined experience in drug development, regulatory affairs and biopharmaceutical finance. Its management and board of directors draw upon deep expertise in clinical trial operations, corporate strategy and commercial planning. With a targeted pipeline and a focus on chronic, progressive diseases, BioVie aims to bring new therapeutic options to patients with limited treatment alternatives.

Key Stats

• Today's Range: $7.27 to $7.27
• 50-Day Range: $6.62 to $12.30
• 52-Week Range: $6.20 to $75.00
• Volume: 2,627 shs
• Average Volume: 186,228 shs
• Market Capitalization: $13.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

BioVie Stock Analysis - MarketRank™

BioVie scored higher than 21% of companies evaluated by MarketBeat, and ranked 851st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioVie.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioVie is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioVie is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioVie has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.52% of the float of BioVie has been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently decreased by 90.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioVie does not currently pay a dividend.

Dividend Growth

BioVie does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.52% of the float of BioVie has been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently decreased by 90.15%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.56

News Sentiment

BioVie has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BioVie this week, compared to 1 article on an average week.

Search Interest

4 people have searched for BIVI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioVie insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.39% of the stock of BioVie is held by insiders.

Percentage Held by Institutions

Only 4.59% of the stock of BioVie is held by institutions.

BIVI Stock Analysis - Frequently Asked Questions

How have BIVI shares performed this year?

BioVie's stock was trading at $20.00 on January 1st, 2025. Since then, BIVI stock has decreased by 65.1% and is now trading at $6.99.

How were BioVie's earnings last quarter?

BioVie Inc. (NASDAQ:BIVI) released its earnings results on Monday, May, 12th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.20) by $1.70.

When did BioVie's stock split?

BioVie shares reverse split before market open on Monday, July 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of BioVie?

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioVie own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioVie investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Hon Hai Precision Industry Co., Ltd. Sponsored GDR (HNHPF), Main Street Capital (MAIN), Ares Capital (ARCC) and PIMCO Dynamic Income Fund (PDI).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/21/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BIVI
• CIK: 1580149
• Web: bioviepharma.com
• Phone: (775) 888-3162
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($79.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -100.88%
• Return on Assets: -78.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.31
• Quick Ratio: 9.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $25.35 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 1,860,000
• Free Float: 1,813,000
• Market Cap: $13.00 million
• Optionable: No Data
• Beta: 0.73